What is Pyrilutamide, and How Does it Help with Androgenic Alopecia or Hair Loss Caused by DHT?

Androgenic alopecia, also known as male or female pattern baldness, is the most common form of hair loss among both men and women. Its main culprit is a hormone called dihydrotestosterone (DHT), derived from testosterone through the enzyme 5-alpha-reductase. DHT binds to androgen receptors found in hair follicles, particularly in the scalp regions predisposed to thinning. Over time, this binding causes miniaturization—shrinking of the hair follicles—leading to thinner, shorter hair until growth stops completely.

Existing treatments like finasteride and minoxidil have been the standard for decades. Finasteride reduces the production of DHT throughout the body, while minoxidil stimulates hair growth by a mechanism that is not well understood. However, systemic DHT inhibition with finasteride has been associated with hormonal side effects in some individuals, including reduced libido and mood changes. This limitation has encouraged research into topical alternatives that act locally on the scalp. Pyrilutamide (KX-826) is one such compound in development that has attracted attention for its targeted mechanism.

Pyrilutamide is an investigational non-steroidal topical antiandrogen developed by Kintor Pharmaceutical. It is not approved as a medicine by any regulator, and it is not available on prescription anywhere; the material sold online under this name is supplied by unregulated research-chemical vendors, of unverified identity and purity. Its proposed mechanism differs from that of finasteride: rather than reducing DHT levels in the bloodstream, pyrilutamide is designed to block DHT from attaching to androgen receptors in the hair follicle. In principle, that means DHT levels could stay unchanged while its effects on the scalp are reduced. That is the rationale behind the compound — localized effect with less systemic exposure — and it is what the trials set out to test, not something established in practice.

Understanding How Pyrilutamide Works

Androgen receptors are proteins within hair follicle cells that interact with androgens—hormones like testosterone and DHT. When DHT binds to these receptors, it activates certain genes that shorten the hair growth cycle, resulting in thinner and weaker hair over time. Pyrilutamide is designed to act as an antagonist, competing with DHT for access to these receptors and blocking its ability to trigger hair follicle shrinkage. Staying localized to the scalp is the intended advantage, as systemic hormonal interference has been a persistent issue with oral antiandrogen treatments.

Clinical research into pyrilutamide is still in progress, and it is important to be clear about where the information comes from: the results below were announced by the sponsor in press releases and registry entries. None of the efficacy data have been published in a peer-reviewed journal, and no independent group has verified them.

The clinical programme registered on ClinicalTrials.gov includes two Phase I studies in healthy men with alopecia (NCT04502901 and NCT04984707, 40 participants each), Phase II studies in men in the United States (NCT05218642, 123 participants) and in China (NCT05940506, 120 participants), a Phase II study in Chinese women (NCT06409650, 160 participants), and a Phase III study in Chinese men (NCT06126965, 740 participants). All of these are listed as completed except the last, whose status on the registry is "unknown". Kintor announced in November 2023 that this 740-patient Phase III, which tested the 0.5% tincture twice daily, did not show a statistically significant difference from placebo in hair count at 24 weeks; the improvement was significant only against baseline. A separate Phase II/III adaptive trial in Chinese men is registered as NCT06622824.

In March 2026, Kintor announced top-line results from the Phase III stage of that adaptive Phase II/III trial: 666 patients across 26 centres in China, randomised and vehicle-controlled, over 24 weeks. The company reported that target-area non-vellus hair count rose by 15.33 hairs/cm² from baseline with the 1.0% tincture twice daily and 14.46 hairs/cm² with the 0.5% tincture, against 4.68 hairs/cm² for the vehicle (P<0.0001), and that no drug-related serious adverse events were seen. This is a company announcement of top-line numbers, not a published paper: the full protocol, the complete adverse-event tables and the per-patient data are not public, and the earlier 740-patient Phase III of the 0.5% tincture (NCT06126965, above) did not beat placebo, so the two Phase III results for that strength point in different directions.

Unlike finasteride, which works by lowering overall DHT levels, pyrilutamide is intended to leave systemic hormone levels alone while blocking the local effects of DHT. The aim is to avoid hormonal side effects such as decreased libido or mood changes; whether it does so over years of use is unknown, because no long-term data exist. Minoxidil, in contrast, does not act on androgens; it was developed as a blood-vessel widener, but how it stimulates hair growth is not well understood. Some researchers have speculated that combining pyrilutamide and minoxidil might offer complementary effects. The sponsor has announced results from an observational study of the combination, but no randomised trial of it has been published in a peer-reviewed journal.

Assessing Safety and Limitations

The sponsor's announcements describe mostly mild local reactions such as redness or dryness, and state that no drug-related serious adverse events occurred and that adverse-event rates did not differ meaningfully from vehicle. Those are the sponsor's summaries; the full adverse-event tables have never been published, so it is not possible to say what has or has not been observed. Because the compound remains investigational, there are no long-term safety data at all.

No regulatory authority—including the U.S. Food and Drug Administration (FDA) and China's NMPA—has approved pyrilutamide for any use. Its efficacy and safety are therefore not established to clinical standards, whatever the top-line press releases say. Pyrilutamide is an experimental approach to androgenic alopecia that targets the androgen receptor at the scalp. The receptor-blocking rationale is coherent, but clinical validation is still under way and none of it is peer-reviewed.

Pyrilutamide is an experimental topical antiandrogen under investigation for androgenic alopecia. It is not a medicine, it is not approved, its long-term safety is unknown, and the product sold online is unregulated. Talk to a doctor or pharmacist before starting, stopping or combining any hair-loss treatment, and before using any unapproved research compound — including pyrilutamide — particularly alongside prescription drugs such as finasteride or dutasteride. A dermatologist can also tell you which approved options apply to your pattern of loss.

No reproductive-safety data on pyrilutamide have been published. Antiandrogens as a class can affect the development of a male fetus, so pyrilutamide is not considered appropriate for anyone who is pregnant, may become pregnant or is breastfeeding, and a partner who is or may be pregnant should avoid contact with treated skin.

References

ClinicalTrials.gov. To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia (Phase II, United States, 123 participants). NCT05218642. https://clinicaltrials.gov/study/NCT05218642

ClinicalTrials.gov. Phase II Study Evaluating the Efficacy and Safety of KX-826 (120 participants). NCT05940506. https://clinicaltrials.gov/study/NCT05940506

ClinicalTrials.gov. Phase III Study of KX-826 With Adult Male Patients With AGA (740 participants). NCT06126965. https://clinicaltrials.gov/study/NCT06126965

Kintor Pharmaceutical. Phase III KX-826 Tincture 1.0% For AGA Reached Primary Endpoint (company announcement, 18 March 2026). https://en.kintor.com.cn/news_details/22.html

Kintor Pharmaceutical. Announcement of top-line results of the Phase III clinical trial of KX-826 for male androgenetic alopecia in China (Hong Kong Stock Exchange announcement, 26 November 2023). https://www.marketscreener.com/quote/stock/KINTOR-PHARMACEUTICAL-LIM-111325374/news/Kintor-Pharmaceutical-Limited-Announces-Results-of-Phase-III-Clinical-Trial-of-KX-826-Topline-Treatm-45442274/